Virtual Biotech Showcase draws over 300 life science companies

By Samantha Black, PhD, ScienceBoard editor in chief

January 5, 2022 -- Biotech Showcase is an investor conference that aims to connect global life science executives with investors. The event was scheduled to take place January 10-13, 2022, in San Francisco; however, on December 16, 2021, the event's organizers announced that it would transition to a virtual on-demand platform.

Over 300 companies are presenting at the virtual event this year, including the following companies:

    • Brainstorm Cell Therapeutics will present a corporate and clinical overview, which will be delivered by Dr. Ralph Kern, president and chief medical officer (CMO) of Brainstorm. The company's NurOwn platform for autologous mesenchymal stem cells-multiple neurotrophic factors cells is an investigational approach that is designed to target disease pathways in neurodegenerative diseases.
    • Citius Pharmaceuticals will provide updates on two of its late-stage products: Mino-Lok, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, and I/Ontak, a novel IL-2R immunotherapy for initial indication in cutaneous T-cell lymphoma.
    • Genprex, represented by Rodney Varner, president and CEO, and Dr. Mark Berger, CMO, will present updates on its gene therapies for cancer and diabetes.
    • ImmunoGenesis will discuss the company's immuno-oncology therapeutic development programs which target immune-excluded cancers. ImmunoGenesis' programs include IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor, and IMGS-501, a novel platform PD-L1/PD-L2 inhibitor that conjugates a STING agonist with optimal PD-1 pathway blockade.
    • Nanobiotix will review updates to its physics-based therapeutic approaches and NBTXR3, a novel product candidate that is designed to destroy tumors through physical cell death when activated by radiotherapy.
    • NeoImmuneTech will speak about new developments relating to its lead candidate, NT-I7, a long-acting human IL-7 that benefits from T cell amplification and enhanced functionality.
    • PharmAbcine, represented by CEO Dr. Jin-San Yoo, will discuss the company's main pipeline candidates, olinvacimab, an anti-VEGFR2 fully human antibody; PMC-403, a Tie2-activating fully human antibody; and PMC-309, an anti-VISTA antagonizing antibody.
    • Last, Transgene will update attendees on clinical programs for two therapeutic vaccines: TG4001, which is targeted for the treatment of human papilloma virus-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform. In addition, the company will discuss new developments relating to its two oncolytic viruses: TG6002, which is for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform.

    Do you have a unique perspective on your research related to life science business? Contact the editor today to learn more.

    ---




    Copyright © 2022 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here